Details
Stereochemistry | ACHIRAL |
Molecular Formula | NO |
Molecular Weight | 30.0061 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[N]=O
InChI
InChIKey=ODUCDPQEXGNKDN-UHFFFAOYSA-N
InChI=1S/HNO/c1-2/h1H
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24560804
http://www.reading.ac.uk/nitricoxide/intro/no/discovery.htm
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24560804
http://www.reading.ac.uk/nitricoxide/intro/no/discovery.htm
In mammals Nitric Oxide (NO) is an important cellular signaling molecule involved in many physiological and pathological processes. It is a powerful vasodilator with a short half-life of a few seconds in the blood. Low levels of nitric oxide production are important in protecting organs such as the liver from ischemic damage. Nitric oxide production is associated with nonalcoholic fatty liver disease (NAFLD) and is essential for hepatic lipid metabolism under starvation. Nitric oxide (INOmax) is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the systemic vasculature. INOmax appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better-ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios. NO, can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively. Because of its importance in neuroscience, physiology, and immunology, NO was proclaimed "Molecule of the Year" in 1992. Research into its function led to the 1998 Nobel Prize for discovering the role of nitric oxide as a cardiovascular signaling molecule (Furchgott, Murad and Ignarro).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11396481
Curator's Comment: NO can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24560804 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | INOMAX Approved UseINOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Launch Date9.4582079E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Increased vulnerability of neuronal cell lines to sodium nitroprusside-mediated toxicity is caused by the decreased level of nitric oxide metabolites. | 1999 Aug-Oct |
|
[Nitric oxide-induced neurotoxicity versus neuroprotection; relationship with selective motor neuronal death]. | 1999 Dec |
|
Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension. | 1999 Dec |
|
Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6. | 1999 Dec |
|
L-arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat. | 2000 |
|
Sodium nitroprusside-induced seizure and taurine release from rat hippocampus. | 2000 |
|
Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. | 2000 |
|
The potential role of nitric oxide in the hypertrophic growth of the left ventricle. | 2000 |
|
Nitric oxide-compromised hypertension: facts and enigmas. | 2000 |
|
Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension. | 2000 |
|
Protective role of intracellular glutathione against nitric oxide-induced necrosis in rat gastric mucosal cells. | 2000 Apr |
|
Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. | 2000 Dec |
|
Residual pulmonary hypertension in children after treatment with inhaled nitric oxide: a follow-up study regarding cardiopulmonary and neurological symptoms. | 2000 Dec |
|
Inhibition of endogenous nitric oxide synthase potentiates ischemia-reperfusion-induced myocardial apoptosis via a caspase-3 dependent pathway. | 2000 Feb |
|
Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition. | 2000 Feb |
|
Copper-dependent formation of disulfide-linked dimer of S100B protein. | 2000 Feb 15 |
|
[Anorectics and pulmonary hypertension]. | 2000 Feb 16 |
|
Pulmonary nitric oxide metabolism following infrarenal aortic cross-clamp-induced ischaemia-reperfusion injury. | 2000 Jan |
|
Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. | 2000 Jul |
|
Nitric oxide induces apoptosis in megakaryocytic cell lines. | 2000 Jun 1 |
|
Recovery from withdrawal of inhaled nitric oxide and kinetics of nitric oxide-induced inhibition of nitric oxide synthase activity in vitro. | 2000 Mar |
|
Protective effect of bilobalide against nitric oxide-induced neurotoxicity in PC12 cells. | 2000 May |
|
Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation. | 2000 May 1 |
|
Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. | 2000 May 9 |
|
The neurogenic vasodilator response to endothelin-1: a study in human skin in vivo. | 2000 Nov |
|
Inhibition of nitric oxide synthase enhances the myocardial toxicity of phenylpropanolamine. | 2000 Nov |
|
Role of nitric oxide in adrenocorticotrophin-induced hypertension: L-arginine effects reversed by N-nitro-L-arginine. | 2000 Nov |
|
Female sex steroids: effects upon microglial cell activation. | 2000 Nov 1 |
|
Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. | 2000 Nov 15 |
|
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells. | 2000 Nov 17 |
|
Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. | 2000 Nov 7 |
|
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension. | 2000 Sep |
|
Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. | 2001 |
|
Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. | 2001 Apr |
|
Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism. | 2001 Apr 15 |
|
Lipopolysaccharide and interferon-gamma-induced nitric oxide production and protein oxidation in mouse peritoneal macrophages are affected by glutathione peroxidase-1 gene knockout. | 2001 Aug 15 |
|
Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. | 2001 Aug 17 |
|
Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. | 2001 Feb |
|
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. | 2001 Feb |
|
Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. | 2001 Jan |
|
Gastric mucosal resistance to acute injury in experimental portal hypertension. | 2001 Jan |
|
Ethanol inhibits cytokine-induced iNOS and sPLA2 in immortalized astrocytes: evidence for posttranscriptional site of ethanol action. | 2001 Jan-Feb |
|
15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. | 2001 Jul 13 |
|
Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced release of nitric oxide. | 2001 Jul 31 |
|
Prostaglandins and nitric oxide mediate superoxide-induced myocardial contractile dysfunction in isolated rat hearts. | 2001 Jun |
|
Nitric oxide inhalation increases alveolar gas exchange by decreasing deadspace volume. | 2001 Jun |
|
Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. | 2001 Jun 14 |
|
Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache. | 2001 Mar |
|
Expression of inducible nitric oxide synthase in primary culture of rat bladder smooth muscle cells by plasma from cyclophosphamide-treated rats. | 2001 Mar 23 |
|
Nitric oxide and chronic HCV and HIV infections. | 2001 May |
Patents
Sample Use Guides
20 ppm, maintained for up to 14 days or until the underlying oxygen desaturation has resolved
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14711563
Curator's Comment: In epithelial cells, NO increased apoptosis by 2.1 +/- 0.2-fold, augmented mRNA expression of Bax, and reduced expression of Bcl-2 compared with basal cultures. In stromal cells, NO increased cell proliferation in a dose-dependent manner, an effect that was blocked by a NO synthase inhibitor.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
603917
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1484
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
340811
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
265708
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
368512
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
551716
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
LOINC |
74369-0
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
NDF-RT |
N0000175940
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
192104
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
756820
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
638918
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
WHO-VATC |
QR07AX01
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
74493
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
621517
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
443914
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
551616
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
CFR |
21 CFR 862.3080
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
NCI_THESAURUS |
C687
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
90595
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
193304
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
INOMAX (AUTHORIZED: RESPITORY INSUFFICIENCY, HYPERTENSION, PULMONARY)
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
403613
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
NDF-RT |
N0000009909
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
WHO-ATC |
R07AX01
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
||
|
DSLD |
1699 (Number of products:1)
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12540MIG
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
Nitric Oxide
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
M7934
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | Merck Index | ||
|
7442
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | RxNorm | ||
|
1246
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
DB00435
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
C695
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
10102-43-9
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
31C4KY9ESH
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
KK-93
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
1948
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200689
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
DTXSID1020938
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
100000089308
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
2509
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
233-271-0
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
NITRIC OXIDE
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
145068
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
SUB03447MIG
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
16480
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
D009569
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY | |||
|
31C4KY9ESH
Created by
admin on Wed Jul 05 23:23:05 UTC 2023 , Edited by admin on Wed Jul 05 23:23:05 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)